Literature DB >> 30665926

Recurrent vulvar melanoma in a patient with neurofibromatosis and gastrointestinal stromal tumour.

Anna Linehan1, Emily Harrold1, Keith Pilson1, John McCaffrey1.   

Abstract

We report a case of a 51-year-old woman with neurofibromatosis who presented in 2012 with postmenopausal bleeding. Excision biopsy of a pigmented lesion of the labia minora was consistent with an ulcerated vulvar BRAF wild type malignant melanoma (MM). Initial excision was followed by radical vulvectomy and adjuvant interferon. Local recurrence in January 2017 was further resected. Positron emission tomography (PET)-CT in May 2017 identified an FDG avid omental deposit; consistent histologically with MM when resected. Postoperative PET-CT in August 2017 demonstrated local recurrence. In the setting of resected stage IV disease and a third local recurrence, the decision was made to instigate immunotherapy. Vulvar melanoma is rare accounting for 0.2% of all melanoma. Presentation is typically a decade later than cutaneous melanoma with a tendency to late metastases and poorer prognosis. Given their rarity the treatment paradigm is less clearly defined and largely extrapolated from that of cutaneous melanomas. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  dermatology; skin cancer; small intestine cancer

Mesh:

Year:  2019        PMID: 30665926      PMCID: PMC6340566          DOI: 10.1136/bcr-2018-224744

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  38 in total

1.  Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.

Authors:  Alexander M M Eggermont; Christian U Blank; Mario Mandala; Georgina V Long; Victoria Atkinson; Stéphane Dalle; Andrew Haydon; Mikhail Lichinitser; Adnan Khattak; Matteo S Carlino; Shahneen Sandhu; James Larkin; Susana Puig; Paolo A Ascierto; Piotr Rutkowski; Dirk Schadendorf; Rutger Koornstra; Leonel Hernandez-Aya; Michele Maio; Alfonsus J M van den Eertwegh; Jean-Jacques Grob; Ralf Gutzmer; Rahima Jamal; Paul Lorigan; Nageatte Ibrahim; Sandrine Marreaud; Alexander C J van Akkooi; Stefan Suciu; Caroline Robert
Journal:  N Engl J Med       Date:  2018-04-15       Impact factor: 91.245

2.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

3.  Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population.

Authors:  M E Zöller; B Rembeck; A Odén; M Samuelsson; L Angervall
Journal:  Cancer       Date:  1997-06-01       Impact factor: 6.860

4.  The efficacy of anti-PD-1 agents in acral and mucosal melanoma.

Authors:  Alexander N Shoushtari; Rodrigo R Munhoz; Deborah Kuk; Patrick A Ott; Douglas B Johnson; Katy K Tsai; Suthee Rapisuwon; Zeynep Eroglu; Ryan J Sullivan; Jason J Luke; Tara C Gangadhar; April K S Salama; Varina Clark; Clare Burias; Igor Puzanov; Michael B Atkins; Alain P Algazi; Antoni Ribas; Jedd D Wolchok; Michael A Postow
Journal:  Cancer       Date:  2016-08-17       Impact factor: 6.860

5.  Somatic activation of KIT in distinct subtypes of melanoma.

Authors:  John A Curtin; Klaus Busam; Daniel Pinkel; Boris C Bastian
Journal:  J Clin Oncol       Date:  2006-08-14       Impact factor: 44.544

Review 6.  Primary melanoma of the female genital system: a report of 10 cases and review of the literature.

Authors:  A Jahnke; J Makovitzky; V Briese
Journal:  Anticancer Res       Date:  2005 May-Jun       Impact factor: 2.480

7.  Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.

Authors:  Alexander M M Eggermont; Stefan Suciu; Mario Santinami; Alessandro Testori; Wim H J Kruit; Jeremy Marsden; Cornelis J A Punt; François Salès; Martin Gore; Rona Mackie; Zvonko Kusic; Reinhard Dummer; Axel Hauschild; Elena Musat; Alain Spatz; Ulrich Keilholz
Journal:  Lancet       Date:  2008-07-12       Impact factor: 79.321

8.  Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.

Authors:  F Stephen Hodi; Christopher L Corless; Anita Giobbie-Hurder; Jonathan A Fletcher; Meijun Zhu; Adrian Marino-Enriquez; Philip Friedlander; Rene Gonzalez; Jeffrey S Weber; Thomas F Gajewski; Steven J O'Day; Kevin B Kim; Donald Lawrence; Keith T Flaherty; Jason J Luke; Frances A Collichio; Marc S Ernstoff; Michael C Heinrich; Carol Beadling; Katherine A Zukotynski; Jeffrey T Yap; Annick D Van den Abbeele; George D Demetri; David E Fisher
Journal:  J Clin Oncol       Date:  2013-06-17       Impact factor: 44.544

9.  Vulvar melanoma with urethral invasion and bladder metastases - a case report and review of the literature.

Authors:  Agnieszka Lemańska; Paulina Banach; Magdalena Magnowska; Andrzej Frankowski; Ewa Nowak-Markwitz; Marek Spaczyński
Journal:  Arch Med Sci       Date:  2015-03-14       Impact factor: 3.318

10.  A first case report of rare synchronous double cancers: malignant cutaneous melanoma and gastrointestinal stromal tumor.

Authors:  Barbara Zegarska; Maciej Nowacki; Katarzyna Pietkun; Wojciech Jozwicki; Tomasz Nowikiewicz; Noor Y Al-Obaidi; Samy L Habib; Wojciech Zegarski
Journal:  Postepy Dermatol Alergol       Date:  2017-08-02       Impact factor: 1.837

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.